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Abstract 
Multiple sclerosis (MS) is the commonest non-traumatic disabling disease to affect young 
adults. The incidence of MS is increasing worldwide, together with the socioeconomic impact 
of disease. The underlying cause of MS, and mechanisms behind this increase remain opaque, 
although complex gene-environment interactions almost certainly play a significant role. The 
epidemiology of MS indicates that low vitamin D, smoking, childhood obesity and infection 
with the Epstein-Barr virus are likely to play a role in disease development. 
Changes in diagnostic methods and criteria mean that we can diagnose people with MS 
increasingly earlier in their disease trajectory. Alongside this, treatments for MS have 
increased exponentially in number, efficacy, and risk. We now face a situation where we 
have the potential to diagnose “pre-symptomatic MS”, and potentially investigate preventive 
strategies for this disease. In this comprehensive review, we discuss MS epidemiology, 
potential aetiological factors and pathology, before moving on to clinical aspects of MS 
diagnosis and management. 
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Introduction 
Multiple sclerosis (MS) is the commonest non-traumatic disabling disease to affect young 
adults[1]. There is increasing incidence and prevalence of MS in both developed and 
developing countries[2], the underlying cause of which remains uncertain. MS is a complex 
disease; many genes modestly increase disease susceptibility in addition to several well 
defined environmental factors, in particular vitamin D or ultraviolet B light (UVB) exposure, 
Epstein-Barr virus (EBV) infection, obesity and smoking[3]. 
MS has historically been classified as an organ specific T-cell mediated autoimmune disease. 
However, the success of B-cell targeted therapies challenges the standard T-cell autoimmune 
dogma[4]. It is traditionally viewed as a two-stage disease, with early inflammation 
responsible for relapsing-remitting disease and delayed neurodegeneration causing non-
relapsing progression, i.e. secondary and primary progressive MS[5,6].   
The emergence of increasingly effective biological therapies and an active approach to 
treating MS, in particular treating to a target of no evident disease activity (NEDA), are 
changing the long-term outcome for people with MS (pwMS). More aggressive immune 
reconstitution therapies (IRTs), that result in a proportion of pwMS entering long-term 
remission, offer a small number of pwMS a potential cure[7]. Recent positive trials of DMTs 
in ‘progressive MS’ offer those with more advanced MS the hope of slowing their disease 
progression, with preservation of residual function[8]. The fact that treatments appear to work 
at multiple stages in the disease course significantly challenges the traditional 2-stage view of 
the natural history of MS[9].     
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Epidemiology and aetiology 
It is often stated that the cause of MS is unknown, however this is not quite correct. EBV, 
sunshine (UVB), smoking and vitamin D, combined with an individual’s genetic background, 
play important roles in the causal pathway that results in MS development[10]. Migration 
studies consistently support MS being secondary to an environmental exposure[11]. Adult 
migrants from low risk countries, such as the West Indies, to Europe are at low risk of 
developing MS; however, children born to migrants in Europe are at high risk. Migration 
studies indicate that environment trumps genetics and argue strongly for prevention studies 
targeting known environmental risk factors. 
Being truly EBV negative protects you from developing MS[12][13]; symptomatic EBV 
infection (i.e. infectious mononucleosis), doubles your chances of getting MS[14]. Evidence 
regarding the mechanism via which EBV increases MS risk is heterogenous; molecular 
mimicry is historically a popular theory [15], more recently EBV-induced B-cell 
immortalisation and/or transformation is been thought to play an important role in disease 
development [16]. 
MS is increasingly a global disease[2] . MS prevalence increases with latitude, however this 
gradient is decreasing in Norway and USA, the two countries where this has been 
studied[17]. The latitudinal gradient in MS prevalence is strongly correlated with UVB 
exposure, which stimulates cutaneous vitamin D (vD) production. Low vD levels, decreased 
intake of vD, reduced outdoor activity and increased MS susceptibility associated with 
genetic polymorphisms causing low vD levels have implicated vD in the causal pathway of 
MS[18]. 
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MS is more common in females, but this has not always been the case. In case series from the 
early 1900s the sex ratio was almost equal. Since then, the sex ratio has been steadily been 
increasing, and is now close to 3:1 (F:M) in most developed countries[19]. Smoking, which 
increases MS risk by approximately 50%, can explain up to 40% of the increased incidence 
of MS in women[20]. Prior to the second world war few women smoked, but the number of 
women smoking rapidly increased post-war, mirroring the increasing incidence of MS in 
women[20]. The observation that organic solvents[21] and smoked tobacco[22], but not oral 
tobacco or snoef[23], are associated with MS has led to the hypothesis that these agents cause 
post-translational modifications via  antigen presentation occurring in the lungs. 
It is likely that MS risk modification occurs throughout life, starting in utero[10]. The month-
of-birth effect and increased concordance in dizygotic twins compared to siblings, indicates 
that the intrauterine environment is important in establishing MS risk; it is unclear whether 
this is due to common environmental exposures, or epigenetic mechanisms, or both[10]. 
There is a genetic influence on MS susceptibility; about one in eight patients have a family 
history of MS[24]. Concordance in female monozygotic twins approaches 30% in the UK and 
Canada, but is as low as ~8.5% in southern Europe[25]. 
The main genetic risk associated with MS resides in HLA-DRB1*15 and/or other loci in 
strong linkage disequilibrium with this allele[26]. Heterozygotes for HLA-DRB1*15:01 have 
an OR of MS >3 and homozygotes >6[26], yet the mechanism remains unknown. It is 
hypothesised that HLA-DRB1*15:01’s role is via antigen presentation, however this does not 
explain the protective effects of class 1 alleles (e.g. HLA-A*02:01)[27]. 
Genome-wide association studies have identified more than 150 single nucleotide 
polymorphisms (SNPs) associated with MS susceptibility[28]. The OR associated with the 
majority of these is small, around 1.1-1.2. Many of these SNPs lie close to genes associated 
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with immune function, typically in regulatory rather than coding regions. Functional variants 
identified include those within IL7R[29], IL2RA[30], TNFR1[31], BAFF[32] and  
CYP2R1[33]. Mendelian randomisation studies have provided evidence for a role of vitamin 
D[33–35] and obesity[36] as independent risk factors causing disease.  
Recent work has uncovered genetic differences between RRMS and PPMS[37] not 
previously detected in GWAS, most likely due to the under-representation of PPMS in these 
cohorts.  Genetic variants associated with other progressive neurological disorders are 
relatively over-represented in progressive MS[37]. Similar genetic risk exists when all MS-
associated alleles are taken in account, indicating additional risk for progressive disease 
superimposed on underlying genetic susceptibility.  Evidence of differential gene 
transcription between RRMS and PPMS[38], again hints at individual differences on a 
background of shared genetic risk. 
Pathology & Immunology 
In Charcot’s original descriptions of the pathology associated with sclerose en plaques, he 
described “sclerosed plaques” affecting the periventricular area, pons, and spinal cord[39]. 
The characteristic pathological hallmark of MS is perivenular inflammatory lesions, leading 
to demyelinating plaques[40]. The inflammatory infiltrates contain T-lymphocytes, 
dominated by MHC Class I restricted CD8+ T-cells; B-cells and plasma cells are also 
present, although in much lower numbers[41]. Oligodendrocyte damage and demyelination 
occur as a result of inflammation. Axons are relatively preserved in the early stages of the 
disease, however as disease progresses irreversible axonal damage develops[42]. The 
“classical active lesion”, with profound lymphocytic inflammation, predominates in RRMS. 
It is seen less commonly in progressive disease, where lesions tend to have an inactive lesion 
core surrounded by a narrow rim of activated microglia and macrophages[43]. 
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Despite a clinical distinction between RRMS and progressive MS, pathologically-defined 
inflammatory changes are seen in both, albeit to a greater degree in relapsing-remitting 
disease. The composition of the inflammatory infiltrate in relapsing-remitting and progressive 
MS is similar, although the proportion of B-cells and plasma cells is higher in progressive 
MS[44]. Whether the cytokine profile or activation stage of T-cells and B-cells differs 
between clinical disease types remains unclear[41]. 
Remyelination is seen in all disease stages, most commonly in progressive disease[41]. 
Patients with SPMS have higher levels of demyelination, and a reduction in axonal density in 
the normal appearing white matter in the cervical spinal cord in PPMS[45]. There is no single 
characteristic histological difference between MS subtypes, instead a difference in the 
proportion of areas showing particular characteristics. Thus whilst three clinical forms of MS 
have been defined, the pathological changes form a continuum. This fits with gradual clinical 
disease evolution in patients, from relapsing-remitting to secondary progressive MS over a 
period of years. 
  
Clinical features 
MS is a journey from being at risk, through the asymptomatic, prodromal and symptomatic 
phases of the disease. MS is typically suspected when a person presents with a clinically 
isolated syndrome (CIS). This can be mono- or poly-symptomatic depending on the location 
of the eloquent lesion(s). The most commonly seen presentations are optic neuritis, brainstem 
and spinal cord syndromes, however numerous other less common presentations exist, 
including cortical presentations, such as dominant parietal lobe syndromes. 
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MS relapses usually develop subacutely over hours to days, reach a plateau lasting several 
weeks, then gradually recover. Gross clinical recovery from relapses often appears complete 
in early MS, however most relapses leave behind some damage. For example, following 
acute optic neuritis gross visual acuity may recover, but colour vision, contrast sensitivity and 
depth perception abnormalities persist. As neuronal reserve is lost, recovery from relapses 
becomes incomplete, and neurological deficits accrue leading to  sustained disability. 
For every clinical attack approximately ten “asymptomatic” lesions are noted on MRI. 
Symptomatology results from a combination of location and size - a small lesion in an 
eloquent area is likely to cause symptoms. Macroscopic, or MRI-visible, lesions are the tip of 
the iceberg; with many more lesions can be seen at microscopic level and even more in deep 
and cortical grey matter. 
Secondary progressive MS typically develops 10-15 years after RRMS onset, with a gradual 
evolution from discrete relapses to slowly progressive disease. There is not a distinct 
transition between disease types, rather relapses occur on a background of subtle progression, 
prior to progression being dominant. The cognitive impairment and progressive MRI atrophy 
seen in early MS indicate that neurodegeneration is present from clinical onset. 
In 5-15% of cases there is a primary progressive onset (primary progressive MS, PPMS), 
typically with gradual accrual of progressive disability involving one dominant neuronal 
system. The commonest presentation is with a progressive spastic paraparesis, but sensory 
ataxia, cerebellar ataxia, cognitive and progressive visual failure are well described PPMS 
variants. 
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There has been a reduction in the proportion of people with PPMS[46]. This is likely related 
to the fact that there are no licensed treatments for PPMS; patients may be labelled as having 
relapsing MS in order to receive treatment, raising ethical questions about the division of MS 
into distinct subtypes. This artificial division of MS into different diseases was driven by the 
pharmaceutical industry to get interferon-beta licensed under the orphan drug act in the US. 
Paediatric MS is considerably rarer than adult onset disease, with a highest reported incidence 
of 2.9/100,000 [47]. The diagnosis is based on repeated episodes of demyelination separated 
by time and space. Differentiating paediatric MS from ADEM can be challenging, as 
paediatric MS may be multifocal at onset [47]. Relapse rates may be higher, but physical 
recovery tends to be more complete. Few treatments are licensed for use in children, and 
referral to a paediatric neurologist with expertise in demyelinating disorders is recommended 
where the diagnosis is suspected. 
Given the above, MS can be thought of as a single disease existing within a spectrum 
extending from relapsing (“inflammatory dominant”) to progressive (“neurodegeneration 
dominant”), in keeping with the 2013 revisions to the clinical course of MS [48]. At present, 
MS definitions place artificial distinctions between patients with progressive and patients 
with relapsing disease. Instead, these subtypes should be seen as points on a continuum of 
disease, which should be expanded to include prodromal (i.e. radiologically isolated) disease. 
Preclinical disease and the at-risk population 
MS has an at-risk period prior to preclinical and clinical phases[49]. Migration studies 
indicate that the time from exposure to environmental risk factors and the onset of disease is 
10-20 years[49]. Pathological studies indicate that the preclinical phase of MS could be 
decades; a Danish series found that a quarter of cases with post-mortem pathological 
evidence of MS were never diagnosed with MS in life[50].  
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MS begins before the first clinical attack; most patients presenting with a CIS have older, 
inactive, lesions on their MRI. Radiologically isolated syndrome (RIS), or “asymptomatic 
MS”, is detected on an MRI done for unrelated reasons, such as headache, head injury or 
screening in the airline industry. Even in these earliest stages there is evidence of end-organ 
damage. MRI in young people with CIS shows brain volume loss compared to controls[51]. 
School performance in children who later develop MS, is poorer than their peers[52], and a 
quarter of patients with RIS have significant cognitive impairment with a profile similar to 
patients with established MS[53]. This appears to indicate that not only is inflammation 
present prior to diagnosis, but there is accompanying neurodegeneration from the start. 
We predict that MS has the potential to become a model neurodegenerative disease, setting 
the stage for presymptomatic diagnosis for other neurodegenerative diseases, in particular 
Alzheimer’s and Parkinson’s disease. The big question is whether society is ready for 
population screening and presymptomatic diagnosis? At some point in time we are going to 
have accept that to have a meaningful impact on the burden associated with 
neurodegenerative disease we are going to have to diagnose these conditions in the 
presymptomatic phase. 
Important differential diagnoses 
Table 1 lists the most common MS differential diagnoses or mimics. Red flags include a first 
relapse at an older age, where vascular disease is more likely. Non-specific white matter 
lesions may be seen in patients with no objective persisting neurological disability and 
history of migraine, although migraine is more common in the MS population[54]. In those 
from low prevalence areas and/or ethnic minorities, differential diagnoses must be carefully 
considered, as neurosarcoidosis, NMOSD and infections such as TB are more likely, and MS-
specific disease modifying therapy may cause a worsening of these diseases. 
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Another red flag is comorbid systemic symptoms and signs; this should alert clinicians to 
exclude multisystem diseases such as SLE, Sjogren’s, Behcet's, Susac’s and other 
vasculitides. MS can coexist with other autoimmune diseases, and so the presence of these 
does not necessarily exclude MS, and the overall clinical picture must be carefully 
considered. 
We would advise a diagnostic lumbar puncture in all patients presenting with possible MS. 
CSF analysis is helpful in both identifying MS mimics and either supporting or arguing 
against a diagnosis of MS. CNS synthesis of oligoclonal IgG bands or OCBs can now be used 
to establish dissemination in time; this will hopefully lead to a renaissance in the use of CSF 
for diagnostic, prognostic and treatment response purposes. 
Table 1: Differential diagnosis of multiple sclerosis 
 
 Investigations 
The diagnosis of MS  remains clinical. However, treatable mimics should be excluded using 
paraclinical investigations where indicated. All patients with suspected MS should have a 
lumbar puncture to help support the clinical diagnosis of MS, exclude MS mimics and to help 
establish a baseline prognostic profile. 
(i)              Serological investigations 
A standard baseline profile should include anti-nuclear factor, vitamin B12, and thyroid 
function. Syphilis and HIV-1 serology are recommended. Depending on the clinical 
presentation HTLV-1&2 serology, anti-aquaporin-4 and anti-MOG antibody screening may 
be indicated. 
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(ii)            MRI 
All patients should undergo MRI imaging of at least the brain and if the presentation is 
spinal, imaging should include the spinal cord. Imaging has a dual purpose - it can help to 
confirm the diagnosis by demonstrating dissemination in both time and space, but it can also 
exclude MS mimics when interpreted by an experienced neuroradiologist. Approximately 2% 
of non-MS related abnormalities picked-up on MRI are incidental findings, e.g. pituitary 
adenomas, pineal cysts, vascular malformations, benign meningiomas and prolapsed 
intervertebral discs. These incidental findings may clinically complicate things, but should 
not distract from diagnosing MS. Visual, auditory and sensory evoked potentials and central 
motor conduction times can establish dissemination in space, and demonstrating slowed 
conduction in patients with equivocal clinical signs and MRI appearances can be useful, 
however they may not add much clinical value. The corollary is that normal 
electrophysiology can be helpful in actively excluding or undiagnosing MS; a clinical 
problem that is much more common than often realised. 
Table 2 summarises the latest set of diagnostic criteria for RRMS[55]. As with previous 
renditions, they have limitations in their clinical implementation. Using baseline OCBs to 
provide evidence of dissemination in time means many patients previously diagnosed with 
CIS now meet the diagnostic criteria for MS. This could create significant problems in 
clinical practice, as guidelines for treatment typically mandate a clinico-radiological 
diagnosis of MS - reclassified patients may acquire a label of MS, but remain ineligible for 
treatment until a second clinical attack or MRI lesion. 
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Table 2: MacDonald Criteria for relapsing remitting and primary progressive Multiple 
Sclerosis 
Some would argue that these criteria do not go far enough as they do not include a diagnosis 
of “asymptomatic MS”. Patients diagnosed as having RIS are not eligible for treatment. This 
is troubling as a proportion of these subjects already have evidence of end-organ damage with 
brain atrophy and cognitive impairment. Approximately 30% go onto develop MS within 5 
years[56], and we may be able to prevent some, or even all, of these patients from developing 
clinically apparent neurological disease with early interventions. Based on the biological 
understanding of MS, early and effective treatment with a DMT will have benefits for 
individual patients.  
The role of MRI in establishing prognosis and treatment response is wide ranging. 
Traditionally, lesion accrual/count, together with “active” lesions (gadolinium-enhancing) has 
been used to estimate disease activity, however correlation with long term outcomes is 
imperfect. The importance of brain atrophy seen on volumetric MRI is increasingly realised, 
as when taken alongside lesion load there is good correlation with long-term clinical 
outcomes [57]. 
High field and double inversion MRI techniques have enabled the visualisation of cortical 
MS lesions, the presence and number of which appear to correlate with clinical outcomes, 
most notably cognitive impairment [58]. Newer MRI techniques, including magnetization 
transfer imaging (MTI), diffusion tensor imaging (DTI), and fMRI are providing insights into 
disease with widespread abnormalities outside of focal lesion development [59], however 
these techniques are not yet in routine clinical practice. 
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Treatment and management of MS 
The treatment of MS can be divided up into disease modifying therapies that tend to be MS-
specific, and symptomatic therapies that are often used in different disease areas to treat 
symptoms resulting from neurological dysfunction. 
(i) Disease modifying therapies 
As the number, and efficacy, of disease modifying therapies has increased, interest in early 
treatment of MS in order to prevent long-term disability has grown. Historically, treatments 
have been immunosuppressant (including fingolimod, natalizumab, ocrelizumab) or 
immunomodulatory (such as interferon-beta, glatiramer acetate, teriflunomide), meaning that 
ongoing treatment is required to maintain suppression of inflammation (and disease activity). 
Immune reconstitution therapies (including alemtuzumab and cladribine), can be given as 
short courses with the aim of producing enduring immunological actions - this is as close as 
we have to a potential cure for MS. This raises the question to as to whether early, or even 
pre-symptomatic, treatment can prevent clinically apparent disease. 
Table 3: Disease modifying therapies currently licensed for the treatment of MS 
Figure 1: (a) Treat-2-target algorithm of NEDA in relapsing-forms of MS; (b) Different 
therapeutic approaches to the “treat to target” algorithm 
Figure 2: New classification of disease-modifying therapies for relapsing forms of MS 
A recent concept in the treatment of MS is “No Evidence of Disease Activity”, or NEDA. 
This has developed from the understanding that clinical relapses are only the tip of the 
iceberg in terms of MS disease activity. Ongoing inflammatory MRI activity occurs in excess 
of clinical relapses; in addition brain atrophy can progress in the absence of overt 
inflammatory disease activity. NEDA is defined by clinical parameters (NEDA-1 and 2 - 
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absence of relapses and clinical disease progression), inflammatory MRI activity (NEDA-3), 
and MRI atrophy and biomarkers (NEDA-4 and 5 - CSF neurofilament levels). In clinical 
practice, this has led to treatment escalation earlier in disease, or early treatment with highly 
active therapies as first line (figures 1b and 3). 
 
Figure 3: NEDA rates in sentinel clinical trials of disease-modifying therapies for relapsing 
forms of MS 
Given that MS is most commonly diagnosed in young women, pregnancy and family 
planning are real concerns for women with MS. Current evidence suggests that pregnancy 
does not increase the risk of long-term disability in MS. However, it is also important that 
disease modifying treatment is not unduly delayed, especially in those with active disease. 
European guidelines briefly discuss issues around pregnancy [60], and UK consensus 
guidelines are currently in press. 
 
(ii) Symptomatic treatments 
Symptomatic therapies refer to pharmaceutical and physical therapies that target symptoms 
arising as a result of central nervous system damage. In general terms these treatments are not 
MS-specific. These include anticholinergics for bladder dysfunction (which may contribute to 
cognitive impairment, necessitating an individualised approach), and medication for 
neuropathic pain (typically tricyclic antidepressants, or gabapentin and derivatives). Treating 
cognitive impairment in MS is complex, and centres around the avoidance of possible 
contributors. Several symptomatic therapies have been licensed specifically for MS. These 
include sativex for spasticity, and fampridine for walking difficulties. An important aspect 
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related to symptomatic therapies is sleep. The prevalence of difficulties with sleeping 
increases as MS disease duration increases, and anxiety, depression and fatigue are more 
common in those reporting poor sleep[61]. A detailed review of these is beyond the scope of 
this article. 
 
         (iii) Treatment of comorbidities contributing to long-term disability 
MS reduces the brain and cognitive reserve that delays the onset of age-related 
neurodegenerative disorders in later life. This may explain a component of the age-related 
progression in older patients with multiple sclerosis. 
Patients with co-morbid disease, in particular vascular disease and smoking, have a poorer 
outcome with more rapidly progressive disease[22]. Recurrent infections such as urinary tract 
infections, may not only result in transient worsening of MS-related symptoms but could 
upregulate mechanisms known to speed-up worsening disability. 
Although the evidence supporting lifestyle and wellness modifications in MS is weak, the 
value of these for general health is important. Patients who exercise do better than those who 
don’t. Patients should be encouraged to have four to five aerobic exercise sessions per week. 
They should avoid vigorous exercise during relapse, as this may cause excessive energy 
demands on an already compromised pathway, and theoretically could increase neuroaxonal 
loss. In patients with significant disability, a bespoke exercise programme should be designed 
to allow them to exercise, which is best done in conjunction with a physiotherapist with 
experience in neurodisability. 
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Despite numerous claims about dietary interventions in MS there are no randomised 
controlled trials to suggest that one diet is superior to the others. Patients should adopt a 
healthy eating pattern that is compatible with their culture; their diet should avoid processed 
foods, in particular sugar and other processed carbohydrates. The WHO recommends no 
more than 5% of dietary calories should be consumed as sugar. In general, a varied diet rich 
in unprocessed foods is recommended. 
 
Future prospects 
By refinement of the MS phenotype, both through expansion to include prodromal cases, and 
extension of disease into a single entity rather than artificially separated disease states, we 
can better understand and treat the illness in question. At present, disease modifying 
treatments are only available to people with clinically relapsing forms of the disease, and a 
minority of those with progressive disease - those showing high levels of inflammatory 
disease on MRI. 
By better understanding MS as a disease continuum, it can be seen that there is potential for 
treatment effects in all MS subtypes. Clinical trial outcome measures for relapsing disease are 
relatively easy to define; in those patients with progressive disease, clinically measurable rate 
of change is slow, and measuring impact on this already slow rate requires more sensitive 
outcome measures than are in current use. Patients with progressive disease have historically 
been denied treatment on the basis of negative clinical trials; if the outcome measures used in 
these trials are insufficiently sensitive to measure treatment effects then it is our 
responsibility as physicians to develop outcome measures with better sensitivity, rather than 
artificially separate disease subtypes. 
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The fact that aetiological factors implicated in MS development have the potential to be 
modified prior to disease development opens the door to the potential for preventive trials. 
However, these would need to be enriched for a high-risk population group, and will take 
many years to set up. In the meantime, early treatment of those at risk of long term disability 
is needed in order to minimise the physical morbidity associated with MS. 
  
Figure legends 
Figure 1: (a) Treat-2-target algorithm of NEDA in relapsing-forms of MS; (b) Different 
therapeutic approaches to the “treat-to-target” algorithm 
Figure 2. New classification of disease-modifying therapies for relapsing forms of MS 
Figure 3. NEDA rates in sentinel clinical trials of disease-modifying therapies for relapsing 
forms of MS 
  
Table legends 
Table 1 Differential diagnosis of multiple sclerosis 
Table 2 Diagnostic criteria for relapsing remitting and primary progressive multiple sclerosis 
Table 3: Disease modifying therapies currently licensed for the treatment of MS 
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Tables 
Table 1 Differential diagnosis of multiple sclerosis 
Clinical 
presentation 
Differential diagnosis Relevant aspects and investigations to 
consider 
Monosymptomatic 
Acute optic 
neuritis (ON) 
Neuromyelitis optica, 
NMO 
Often associated with severe visual loss. May 
be bilateral rapidly sequential ON. AQ4 and 
MOG antibodies. Possible additional MRI 
lesions in area postrema or diencephalon. 
Leber hereditary ON Genetic testing. 
Toxic/nutritional ON Clinical history, alcohol and tobacco use. B12, 
methylmalonic acid and/or plasma 
homocysteine. 
Non-arteritic ischaemic 
ON 
Age - usually in older patients. Clinical history 
and examination; vascular risk factors. 
Arteritic ischaemic ON Age - usually occurs in patients aged >70. 
Autoimmune/ANA screen, ESR. 
Transverse 
myelitis 
(TM)/spinal 
cord 
syndrome 
Neuromyelitis optica, 
NMO 
Consider if long segment transverse myelitis 
(>3 segments) involving much of the central 
spinal cord with oedema and gadolinium 
enhancement. Additional MRI lesions in area 
postrema or diencephalon. May have previous 
optic neuritis. AQ4 and MOG antibodies. 
T.M associated with 
systemic autoimmune 
disease 
May have systemic features or clinical history 
of autoimmune disease (rash, renal 
involvement, dry eyes etc). ANA screen, ESR. 
Anterior spinal artery 
occlusion 
Sudden, catastrophic onset with anterior spinal 
cord syndrome. Usually older patients and/or 
those with vascular risk factors. MRI may 
differentiate with bilateral anterior involvement 
in watershed mid thoracic area typical. 
Arteriovenous 
fistula/malformation 
Stepwise onset, mixed upper and lower motor 
neurone. MRI and/or spinal angiography may 
make the diagnosis with dilated and/or tortuous 
dural veins seen. 
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Radiation myelopathy Clinical history, MRI may show vertebral 
changes 
B12/folate deficiency Clinical history of dietary insufficiency and/or 
nitrous oxide inhalation. FBC/serological 
changes may co-exist. May have additional 
optic neuropathy and/or peripheral nerve 
involvement. Long segment changes in dorsal 
columns on MRI. Serum B12 and plasma 
homocysteine/methylmalonic acid levels. 
Copper deficiency Clinical history of gastrectomy or excessive 
zinc intake. Long segment changes in dorsal 
columns on MRI. Serum copper levels 
diagnostic. 
Brainstem Ischaemic event (stroke, 
TIA) 
Clinical history, age - usually in older patients. 
MRI and CSF may help differentiate. 
Space occupying lesion More gradual onset, MRI can differentiate 
Migraine More rapid resolution, may have severe 
headache. MRI can help differentiate. 
Brainstem encephalitis 
(Bickerstaff’s) 
Patients may be encephalopathic and/or 
obtunded. MRI and CSF can help differentiate. 
Chronic lymphocytic 
inflammation with 
pontine perivascular 
enhancement responsive 
to steroids (CLIPPERS) 
Clinical history - may have peripheral nerve 
involvement in brainstem. 
Polysymptomatic 
  Migraine More rapid resolution, may have severe 
headache. MRI can help differentiate. 
Ischaemic event (stroke, 
TIA, small vessel 
disease) 
Clinical history, age - usually in older patients. 
MRI and CSF may help differentiate. 
Cerebral autosomal 
dominant arteriopathy 
with cortical infarcts and 
leukoencephalopathy 
(CADASIL) 
Family and clinical history - typically 
migraine, stroke-like events and prominent 
cognitive involvement. MRI can show typical 
appearances. NOTCH-3 mutation testing 
diagnostic. 
Sarcoidosis May have multisystem involvement - CT chest 
may help. OCBs often negative in CSF. 
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Systemic autoimmune 
disease 
May have systemic features or clinical history 
of autoimmune disease (rash, renal 
involvement etc). ANA screen, ESR, Ro/La, 
SCL-70 
Primary CNS vasculitis Patients often encephalopathic. MRI shows 
small ischaemic (rather than inflammatory) 
lesions. MRI angiography can be helpful. 
Susac’s syndrome Clinical history of encephalopthy, deafness 
and/or visual impairment may be present – 
most patients do not have complete triad at 
presentation. Branch retinal infarcts on 
fundoscopy. Characteristic callosal lesions on 
MRI. Fluroscein angiography mandatory if 
diagnosis suspected. 
Neuro-Bechet’s Systemic and/or additional CNS features - 
venous sinus thrombosis and meningitis. 
Associated with HLA-B5. 
Acute disseminated 
encephalomyelitis - 
ADEM 
Acute polysymptomatic onset, often post-viral. 
MRI shows large demyelinating lesions all of 
similar age with gadolinium enhancement but 
without T1 black holes at presentation. 
Progressive disease 
  Spinal cord compression 
by disc, tumour, syrinx 
etc 
MRI 
Progressive metabolic 
myelopathy 
Clinical history, copper/B12 levels, MRI 
Genetic progressive 
spastic 
paraparesis/cerebellar 
ataxia (HSP, SCA) 
Family and clinical history, relevant genetic 
test 
Leukodystrophies Very long chain fatty acids (especially in 
males) and white cell enzymes 
Infectious causes - 
HTLV and HIV 
Clinical (+/- family history), HTLV 1 and HIV 
serology 
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Table 2 Diagnostic criteria for relapsing remitting and primary progressive multiple 
sclerosis 
  MacDonald 2010 (relapsing 
remitting MS) 
MacDonald 2017 (relapsing remitting MS) 
DIS Either: Either: 
  i) Objective clinical evidence of 
⋝2 lesions, or objective clinical 
evidence of 1 lesion with 
reasonable historical evidence of 
a prior attack involving a 
different CNS site or 
i) Objective clinical evidence of ⋝2 lesions, or 
objective clinical evidence of 1 lesion with 
reasonable historical evidence of a prior attack 
involving a different CNS site or 
  ii) ⋝1 T2 lesion in at least 2 of 4 
MS-typical regions of the CNS 
(periventricular, juxtacortical, 
infratentorial, spinal cord); 
symptomatic lesions in patients 
with brainstem or spinal cord 
syndromes are excluded 
ii) ⋝1 T2 lesion in at least 2 of 4 MS-typical 
regions of the CNS (periventricular, 
juxtacortical, infratentorial, spinal cord) 
DIT Either: Either: 
  (i) ⋝2 attacks separated by at 
least 1 month, or 
(i) ⋝2 attacks separated by at least 1 month, or 
  (ii) Simultaneous presence of 
asymptomatic gadolinium 
enhancing and non-enhancing 
lesions at any time, or 
(ii) Simultaneous presence of asymptomatic 
gadolinium enhancing and non-enhancing 
lesions at any time, or 
  (iii) A new T2 and/or gadolinium-
enhancing lesion on follow-up 
MRI irrespective of its timing 
with reference to a baseline scan 
(iii) A new T2 and/or gadolinium-enhancing 
lesion on follow-up MRI irrespective of its 
timing with reference to a baseline scan, or 
    (iv) Demonstration of CSF-specific OCBs (as a 
substitute for DIT 
MacDonald 2010 criteria for primary progressive MS 
(i) 1 year of disease progression (retrospectively or prospectively determined) and 
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(ii) 2 out of 3 of: Evidence of DIS in the brain based on ⋝1 T2 lesion in at least one area 
characteristic for MS (periventricular, juxtacortical, infratentorial), 
and/or 
  Evidence of DIS in the spinal cord based on ⋝2 T2 lesions in the cord 
and/or 
  Positive CSF (OCBs on isoelectric focussing and/or elevated IgG index) 
    
  
DIS: dissemination in space 
DIT: dissemination in time 
CNS: central nervous system 
OCB: oligoclonal band 
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Table 3: Disease modifying therapies currently licensed for the treatment of MS 
 Trade 
Name 
Mechanism 
of action 
Efficac
y 
Route of 
administ
ration 
Main adverse 
effects 
Monitoring 
requirements 
  
First line injectable therapies 
Interferon
-beta 1a 
and 1b 
Avone
x, 
Rebif, 
Betase
ron, 
Betafe
ron, 
Extavi
a 
Immunomo
dulatory, 
pleiotropic 
immune 
effects 
Modera
te 
Variable 
and 
depends 
on 
formulati
on 
Injection site 
reactions, flu-
like symptoms, 
abnormal 
LFTs, 
lymphopaenia, 
leukopaenia 
Baseline: FBC, 
U&E, LFTs, 
TFTs, SPE, urine 
protein. 
Follow-up: 1-
month, 3-month, 
6-month and 6-
monthly FBC, 
U&E and LFTs. 
TFTs 12 monthly. 
NABs 12 & 24 
months 
Peg-IFN-
beta-1a 
Plegri
dy 
Pegylated 
(long-
circulating 
half-life).  
Immunomo
dulatory, 
pleiotropic 
immune 
effects 
Modera
te 
Prefilled 
syringe 
125ug sc 
2-weekly 
Injection site 
reactions, flu-
like symptoms, 
abnormal 
LFTs, 
lymphopaenia, 
leukopaenia 
Baseline: FBC, 
U&E, LFTs, 
TFTs, SPE, urine 
protein. 
Follow-up: 1-
month, 3-month, 
6-month and 6-
monthly FBC, 
U&E and LFTs. 
TFTs 12 monthly. 
NABs 12 & 24 
months 
Glatirame
r acetate 
Copax
one 
Immunomo
dulatory, 
pleiotropic 
immune 
effects 
Modera
te 
Prefilled 
syringe 
20mg sc 
daily or 
40mg sc 
TIW 
Injection site 
reactions, 
lipoatrophy, 
flushing 
reactions 
None required 
  
Oral immunomodulatory therapies 
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Dimethyl 
fumarate 
Tecfid
era 
Pleotropic, 
NRF2 
activation, 
downregulat
ion of 
NFΚβ 
Modera
te/High 
240mg 
twice 
daily PO 
Flushing, 
gastrointestinal 
symptoms 
(dyspepsia, 
cramps and 
diarrhoea), 
lymphopaenia, 
abnormal 
LFTs, 
proteinuria, 
PML 
Baseline: FBC, 
U&E, LFTs, urine 
protein. 
Follow-up: FBC 
and urine protein 
3 monthly for a 
year, then 6-
monthly. 
Terifluno
mide 
Aubag
io 
Dihydro-
orotate 
dehydrogen
ase inhibitor 
(reduced de 
novo 
pyrimidine 
synthesis), 
anti-
proliferative 
Modera
te 
7 or 
14mg 
daily PO 
(7mg 
dose only 
licensed 
in the 
USA) 
Hair thinning, 
gastrointestinal 
symptoms 
(nausea, 
diarrhoea), 
abnormal 
LFTs, 
leukopaenia, 
Baseline: BP, 
FBC, U&E, 
LFTs, urine 
protein. 
Follow-up: 
Fortnightly LFTs 
for 6 months then 
every 8 weeks. 
Weekly LFT if 
ALT 2-3x ULN. 
3-monthly FBC 
for 1 year then 6-
monthly. 
  
Oral immunosuppressive therapy 
  
Fingolimo
d 
Gilen
ya 
Selective 
S1P 
modulator, 
prevents 
egress of 
lymphocyte
s from 
lymph 
nodes 
High 0.5mg 
daily PO 
Bradycardia 
(first dose), 
hypertension, 
bronchospasm, 
lymphopaenia, 
abnormal 
LFTs, 
infections, 
basal cell 
carcinoma, 
macular 
oedema, 
opportunistic 
infections 
(PML, 
cryptococcosis
, etc.) 
Baseline: BP, 
FBC, U&E, 
LFTs, TFTs, 
serum 
immunoglobulin 
levels, serology 
(VZV, HIV1&2, 
hepatitis B&C, 
syphilis), TB 
elispot, ECG. 
Follow-up: 3-
monthly FBC, 
U&E and LFTs. 
TFTs 12 monthly. 
OCT at 3 months 
for macular 
oedema. 
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Intravenous immunosuppressive therapies 
  
Natalizum
ab 
Tysab
ri 
Anti-VLA4, 
selective 
adhesion 
molecule 
inhibitor 
Very 
high 
300mg 
IV 4-
weekly 
Infusion 
reactions, 
progressive 
multifocal 
leukoencephal
opathy (PML) 
Baseline: FBC, 
U&E, LFTs, 
JCV-serology. 
Follow-up: LFTs 
3 monthly for a 
year. 
NABs at 12 
months. JCV 
serology 6-
monthly. 
Ocrelizum
ab 
Ocrev
us 
Anti-CD20, 
B-cell 
depleter 
Very 
high 
Initially 
300mg 
IV, 
followed 
2-weeks 
later by 
2nd dose 
of 300mg 
IV. 
Subseque
nt dosing 
600mg 
IV 6 
monthly 
Infusion 
reactions, 
infections, 
possible 
hypogammagl
obulinemia 
with prolonged 
use 
Baseline: FBC, 
U&E, LFTs, 
TFTs, serum 
immunoglobulin 
levels, serology 
(VZV, HIV1&2, 
hepatitis B&C, 
syphilis), TB 
elispot, cervical 
smear. 
Follow-up: annual 
serum 
immunoglobulin 
levels 
  
Induction/immune reconstitution therapies 
  
Alemtuzu
mab 
Lemtr
ada 
Anti-CD52, 
non-
selective 
immune 
depleter 
Very 
high 
12mg IVI 
x 5 days 
yr-1, 
12mg IVI 
x 3 days 
yr-2 
Infusion 
reactions, 
infections, 
opportunistic 
infections, 
leukopaenia, 
secondary 
autoimmunity 
(thyroid, ITP, 
renal, etc.) 
Baseline: FBC, 
U&E, LFTs, 
TFTs, serum 
immunoglobulin 
levels, serology 
(VZV, HIV1&2, 
hepatitis B&C, 
syphilis), TB 
elispot, cervical 
smear. 
Follow-up (for 48 
months after last 
course): monthly 
FBC, U&E and 
urine analysis and 
3-monthly TFTs. 
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Cladribin
e 
Mave
nclad 
Deoxyadeno
sine 
(purine) 
analogue, 
adenosine 
deaminase 
inhibitor, 
selective T 
and B cell 
depletion 
High 10mg 
tablets: 
cumulati
ve dose 
of 
3.5mg/kg 
over 2 
years. 
Tablets 
given for 
4-5 days 
in month 
1 & 2 in 
yr 1 and 
the cycle 
is 
repeated 
in yr 2 
(8-10 
days of 
treatment 
per year) 
Lymphopaenia
, infections (in 
particular 
herpes zoster) 
Baseline: FBC, 
U&E, LFTs, 
TFTs, serum 
immunoglobulin 
levels, serology 
(VZV, HIV1&2, 
hepatitis B&C, 
syphilis), TB 
elispot, pregnancy 
test and cervical 
smear. Follow-up: 
FBC 2 and 6 
months after start 
of treatment in 
each treatment 
year. 
Mitoxantr
one 
Novat
rone 
Immune 
depleter 
(topoisomer
ase 
inhibitor) 
Very 
high 
12 
mg/m2 
IVI 3 
monthly 
for 2 
years; 
maximu
m dose of 
140mg/m
2 
Leukopaenia, 
hair loss, 
nausea, 
vomiting, 
infections, 
cardiomyopath
y, 
amenorrhoea 
Baseline: FBC, 
U&E, LFTs, 
TFTs, SPE, serum 
immunoglobulin 
levels, serology 
(VZV, HIV1&2, 
hepatitis B&C, 
syphilis), TB 
elispot. 
Follow-up: 3-
monthly 
(predosing) FBC, 
U&E and LFTs. 
TFTs 12 monthly. 
Autologou
s 
haematop
oietic stem 
cell 
transplant
ation 
(AHSCT) 
 Autologous 
stem cell 
transplantati
on using 
standard 
haematolog
y protocols 
Very 
high 
Accordin
g to local 
protocols 
Adverse events 
related to 
induction 
chemotherapy 
Dictated by 
haematology 
protocols 
  
PML: progressive multifocal leukoencephalopathy 
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PO: oral 
SC: subcutaneous 
IV: intravenous 
SPE: Serum protein electrophoresis 
TFT: thyroid function test 
VZV: varicella zoster 
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